National Marrow Donor Program, Minneapolis, Minnesota; Hematology/Oncology/Blood and Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Transplant Cell Ther. 2022 Dec;28(12):802-809. doi: 10.1016/j.jtct.2022.09.020. Epub 2022 Sep 30.
The American Society for Transplantation and Cellular Therapy (ASTCT) and the National Marrow Donor Program (NMDP) have formed the ACCESS Initiative to address and reduce barriers to hematopoietic cell transplantation (HCT) and cellular therapy (CT) in an effort to ensure equal access and outcomes for all patients in need. In addition to cellular therapy physicians, the initiative includes program administrators, health policy and health equity experts, health service researchers, participants from commercial payer organizations, and federal stakeholders. The inaugural ASTCT-NMDP ACCESS Workshop was held in Washington, DC on July 28 and 29, 2022, wherein committee members met to discuss and to define goals for 3 focus areas: awareness, poverty, and racial and ethnic inequity. This position paper reviews the mission, vision, and structure of the ACCESS Initiative and the proceedings from the inaugural workshop and provides an initial roadmap for the group's efforts at reducing access barriers and outcome disparities in HCT/CT.
美国移植与细胞治疗学会(ASTCT)和全国骨髓供者计划(NMDP)成立了 ACCESS 倡议,旨在解决造血细胞移植(HCT)和细胞治疗(CT)中的障碍,并努力确保所有有需要的患者都能平等获得治疗和结果。该倡议除了细胞治疗医生外,还包括项目管理人员、卫生政策和卫生公平专家、卫生服务研究人员、商业支付方组织的参与者和联邦利益相关者。首次 ASTCT-NMDP ACCESS 研讨会于 2022 年 7 月 28 日至 29 日在华盛顿特区举行,委员会成员在会上讨论并确定了三个重点领域的目标:意识、贫困和种族与民族不平等。本立场文件回顾了 ACCESS 倡议的使命、愿景和结构,以及首次研讨会的会议记录,并为该组织在减少 HCT/CT 中的获得障碍和结果差异方面的努力提供了初步路线图。